GlobeNewsWire
22 Jul 2026, 02:46 UTC · 15w ago
Impact · against what's priced in
Dyne Therapeutics is experiencing immediate share dilution from a $375 million public offering, though the capital infusion secures its clinical runway. The impact on the investment banks is negligible as these routine fee-generating activities are typical of their business models.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Dyne Therapeutics has priced an upsized public offering of 18.3 million shares of common stock at $20.50 per share.
So whatPublic offerings typically lead to immediate share price dilution and can create short-term downward pressure on the stock.
More negative than 86% of claims this week
The company expects to raise gross proceeds of approximately $375.15 million from the offering.
Continue reading
5 related stories
The issuance of 18.3 million shares at $20.50 creates immediate dilution for shareholders, though the $375.15 million in gross proceeds strengthens the balance sheet for its neuromuscular disease programs.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 62% of claims this week
Underwriters have been granted a 30-day option to purchase an additional 2.745 million shares.
So whatThe potential for additional share issuance increases the total possible dilution for existing shareholders.
More negative than 65% of claims this week
Which stocks this story touches
More positive than 53% of ticker scores this week
The company is successfully raising a significant amount of capital through an upsized public offering to fund its clinical programs.
More positive than 47% of ticker scores this week
Morgan Stanley is serving as a joint book-running manager for the public offering, generating fee income.
More positive than 47% of ticker scores this week
Evercore is serving as a joint book-running manager for the public offering, generating fee income.
More positive than 47% of ticker scores this week
Jefferies is serving as a joint book-running manager for the public offering, generating fee income.
More positive than 47% of ticker scores this week
Raymond James is serving as a joint book-running manager for the public offering, generating fee income.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1d ago
More positive than 15% of relationship scores this week
[a_to_b] Evercore is acting as a joint book-running manager for Dyne Therapeutics' public offering.
More positive than 15% of relationship scores this week
[a_to_b] Raymond James is acting as a joint book-running manager for Dyne Therapeutics' public offering.
More positive than 15% of relationship scores this week
[a_to_b] Jefferies is acting as a joint book-running manager for Dyne Therapeutics' public offering.
—
No price for DYN right now — the quote feed didn't answer.
DYN chart →
